Articles by tag: intellia

CRISPR Therapy HAE: Phase 3 Data from Intellia at EAACI 2026

Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.

Intellia CRISPR therapy: phase 3 data on edema — breakthrough

Intellia presented long-awaited phase III data of CRISPR therapy lonvo-z for hereditary angioedema: 87% reduction in attacks, 62% of patients attack-free. Learn about the breakthrough in in vivo genome editing.

CRISPR therapy in vivo: Intellia study 87% efficacy in HAE

Phase 3 HAELO: single CRISPR infusion reduced hereditary angioedema attacks by 87% vs placebo. First in vivo therapy on the verge of registration. Details, insights, forecasts.

Intellia CRISPR therapy: FDA filing for lonvo-z for HAE

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.